Want to see OMCL full AI Analyst Report?
OMCL Stock Chart & Stats
$41.00
-$0.05(-0.12%)
At close: 4:00 PM EDT
$41.00
-$0.05(-0.12%)
Day’s Range― - ―
52-Week Range$29.06 - $55.00
Previous CloseN/A
Volume116.00K
Average Volume (3M)719.86K
Market Cap
$1.62B
Enterprise Value$1.80K
Total Cash (Recent Filing)$307.01M
Total Debt (Recent Filing)$200.00M
Price to Earnings (P/E)41.6
Beta0.79
Next Earnings
Nov 04, 2026EPS Estimate
0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.85
Shares Outstanding45,614,883
10 Day Avg. Volume689,632
30 Day Avg. Volume719,864
Financial Highlights & Ratios
PEG Ratio-12.17
Price to Book (P/B)1.69
Price to Sales (P/S)1.76
P/FCF Ratio23.97
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$55.00Price Target Upside34.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)2.26
Revenue Forecast (FY)$1.24B
Bulls Say, Bears Say
Bulls Say
Revenue And Profitability ReboundThe sharp revenue recovery and improved operating margin indicate better execution and renewed demand for Omnicell’s solutions. If sustained, this can strengthen earnings power, support reinvestment and improve profitability despite the company’s historically uneven results.
Strong Cash Generation And LiquidityConsistently positive free cash flow and substantial liquidity provide flexibility to fund product development, customer deployments and leasing initiatives. This internally generated funding also reduces dependence on external capital and supports resilience through operating volatility.
Product Pipeline And Platform ExpansionThe roadmap extends Omnicell’s automation and cloud-platform offering, creating opportunities to deepen health-system relationships and win enterprise deployments. Competitive Titan XT wins and specialty pharmacy engagements provide evidence that upcoming products can expand the addressable opportunity.
Bears Say
Thin And Historically Volatile ProfitabilityDespite the recent rebound, limited bottom-line margin leaves earnings sensitive to cost increases, revenue timing and execution setbacks. The history of losses also suggests that improved profitability is not yet fully established as a durable operating characteristic.
Uncertain Product Bookings TimingLarge health-system purchases require multi-quarter or multi-year capital approvals, making bookings and hardware revenue difficult to forecast. Delays can defer deployments, weaken near-term growth visibility and create uneven utilization of the company’s sales and implementation capacity.
Margin Pressure From Costs And One-Time BenefitHigher memory costs are expected to reduce full-year gross margins, while the tariff refund will not recur to support future comparisons. Together, these factors make reported profitability less representative of underlying run-rate performance and constrain near-term margin expansion.
Omnicell News
OMCL FAQ
What was Omnicell’s price range in the past 12 months?
Omnicell lowest stock price was $29.06 and its highest was $55.00 in the past 12 months.
What is Omnicell’s market cap?
Omnicell’s market cap is $1.62B.
When is Omnicell’s upcoming earnings report date?
Omnicell’s upcoming earnings report date is Nov 04, 2026 which is in 74 days.
How were Omnicell’s earnings last quarter?
Omnicell released its earnings results on Jul 30, 2026. The company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.468 by $0.472.
Is Omnicell overvalued?
According to Wall Street analysts Omnicell’s price is currently Undervalued.
Does Omnicell pay dividends?
Omnicell does not currently pay dividends.
What is Omnicell’s EPS estimate?
Omnicell’s EPS estimate is 0.42.
How many shares outstanding does Omnicell have?
Omnicell has 45,614,883 shares outstanding.
What happened to Omnicell’s price movement after its last earnings report?
Omnicell reported an EPS of $0.94 in its last earnings report, beating expectations of $0.468. Following the earnings report the stock price went down -10.362%.
Which hedge fund is a major shareholder of Omnicell?
Currently, no hedge funds are holding shares in OMCL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Omnicell Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$55.00 (34.15% Upside)
$55.00 (34.15% Upside)
Blogger Sentiment
Bullish
OMCL Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 151.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 8.7%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
45.75%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.83%
Trailing 12-Months
Company Description
Omnicell
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
OMCL Company Deck
OMCL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents solid operating and financial execution in Q2 — revenue at the high end of guidance, strong cash generation, several strategic product wins and a materially larger pipeline — coupled with raised full-year profitability targets. However, key near-term risks include timing uncertainty around large product bookings (broad bookings range), a one-time tariff refund that boosted Q2 results, memory chip cost pressures (~$6M impact, ~50–80 bps margin effect), and slower consumables/ARR timing. Overall, the tone balances strong execution and long-term opportunity against near-term timing and supply-chain headwinds.View all OMCL earnings summariesOMCL Stock 12 Month Forecast
Average Price Target
$55.00
▲(34.15% Upside)
Technical Analysis
Ownership Overview
2.95% Insiders
29.41% Mutual Funds
15.95% Other Institutional Investors
17.25% Public Companies and
Individual Investors